These findings indicate that immunohistochemical analysis of CD8+ TILs and RHAMM expression can not only refine prognostic subgroups in rectal cancer but could be utilised to identify a subgroup of early rectal cancer patients at high risk of adverse prognosis. The gene discussed is CD8A; the disease is rectal cancer.